Cargando…

Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy

SIMPLE SUMMARY: In this study, we investigated the longitudinal changes and predictive value of multiparametric MRI (mpMRI) features of prostate cancer patients receiving Lattice Extreme Ablative Dose (LEAD) boost radiotherapy (RT). Ninety-five mpMRI from 25 patients, acquired pre-RT and at 3 time p...

Descripción completa

Detalles Bibliográficos
Autores principales: Algohary, Ahmad, Alhusseini, Mohammad, Breto, Adrian L., Kwon, Deukwoo, Xu, Isaac R., Gaston, Sandra M., Castillo, Patricia, Punnen, Sanoj, Spieler, Benjamin, Abramowitz, Matthew C., Dal Pra, Alan, Kryvenko, Oleksandr N., Pollack, Alan, Stoyanova, Radka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496901/
https://www.ncbi.nlm.nih.gov/pubmed/36139635
http://dx.doi.org/10.3390/cancers14184475
_version_ 1784794384838950912
author Algohary, Ahmad
Alhusseini, Mohammad
Breto, Adrian L.
Kwon, Deukwoo
Xu, Isaac R.
Gaston, Sandra M.
Castillo, Patricia
Punnen, Sanoj
Spieler, Benjamin
Abramowitz, Matthew C.
Dal Pra, Alan
Kryvenko, Oleksandr N.
Pollack, Alan
Stoyanova, Radka
author_facet Algohary, Ahmad
Alhusseini, Mohammad
Breto, Adrian L.
Kwon, Deukwoo
Xu, Isaac R.
Gaston, Sandra M.
Castillo, Patricia
Punnen, Sanoj
Spieler, Benjamin
Abramowitz, Matthew C.
Dal Pra, Alan
Kryvenko, Oleksandr N.
Pollack, Alan
Stoyanova, Radka
author_sort Algohary, Ahmad
collection PubMed
description SIMPLE SUMMARY: In this study, we investigated the longitudinal changes and predictive value of multiparametric MRI (mpMRI) features of prostate cancer patients receiving Lattice Extreme Ablative Dose (LEAD) boost radiotherapy (RT). Ninety-five mpMRI from 25 patients, acquired pre-RT and at 3 time points following RT were analyzed. Five regions of interest were analyzed, related to tumor, peritumoral, and normally-appearing tissues. We identified significant changes in the imaging parameters following RT in all regions. By using selected features at the four scan points and their differences (Δ radiomics), we were able to build viable predictive models for endpoint biopsy positivity. Our study demonstrates that RT causes significant changes to quantitative imaging features in both tumorous and normally-appearing tissues. Because of the noninvasive nature of the mpMRI, acquiring multiple exams post-RT is feasible to monitor treatment response. Several quantitative imaging features are promising predictors of treatment failure based on post-treatment positive biopsy, a strong marker for clinically relevant endpoints. ABSTRACT: We investigated the longitudinal changes in multiparametric MRI (mpMRI) (T2-weighted, Apparent Diffusion Coefficient (ADC), and Dynamic Contrast Enhanced (DCE-)MRI) of prostate cancer patients receiving Lattice Extreme Ablative Dose (LEAD) radiotherapy (RT) and the capability of their imaging features to predict RT outcome based on endpoint biopsies. Ninety-five mpMRI exams from 25 patients, acquired pre-RT and at 3-, 9-, and 24-months post-RT were analyzed. MRI/Ultrasound-fused biopsies were acquired pre- and at two-years post-RT (endpoint). Five regions of interest (ROIs) were analyzed: Gross tumor volume (GTV), normally-appearing tissue (NAT) and peritumoral volume in both peripheral (PZ) and transition (TZ) zones. Diffusion and perfusion radiomics features were extracted from mpMRI and compared before and after RT using two-tailed Student t-tests. Selected features at the four scan points and their differences (Δ radiomics) were used in multivariate logistic regression models to predict the endpoint biopsy positivity. Baseline ADC values were significantly different between GTV, NAT-PZ, and NAT-TZ (p-values < 0.005). Pharmaco-kinetic features changed significantly in the GTV at 3-month post-RT compared to baseline. Several radiomics features at baseline and three-months post-RT were significantly associated with endpoint biopsy positivity and were used to build models with high predictive power of this endpoint (AUC = 0.98 and 0.89, respectively). Our study characterized the RT-induced changes in perfusion and diffusion. Quantitative imaging features from mpMRI show promise as being predictive of endpoint biopsy positivity.
format Online
Article
Text
id pubmed-9496901
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94969012022-09-23 Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy Algohary, Ahmad Alhusseini, Mohammad Breto, Adrian L. Kwon, Deukwoo Xu, Isaac R. Gaston, Sandra M. Castillo, Patricia Punnen, Sanoj Spieler, Benjamin Abramowitz, Matthew C. Dal Pra, Alan Kryvenko, Oleksandr N. Pollack, Alan Stoyanova, Radka Cancers (Basel) Article SIMPLE SUMMARY: In this study, we investigated the longitudinal changes and predictive value of multiparametric MRI (mpMRI) features of prostate cancer patients receiving Lattice Extreme Ablative Dose (LEAD) boost radiotherapy (RT). Ninety-five mpMRI from 25 patients, acquired pre-RT and at 3 time points following RT were analyzed. Five regions of interest were analyzed, related to tumor, peritumoral, and normally-appearing tissues. We identified significant changes in the imaging parameters following RT in all regions. By using selected features at the four scan points and their differences (Δ radiomics), we were able to build viable predictive models for endpoint biopsy positivity. Our study demonstrates that RT causes significant changes to quantitative imaging features in both tumorous and normally-appearing tissues. Because of the noninvasive nature of the mpMRI, acquiring multiple exams post-RT is feasible to monitor treatment response. Several quantitative imaging features are promising predictors of treatment failure based on post-treatment positive biopsy, a strong marker for clinically relevant endpoints. ABSTRACT: We investigated the longitudinal changes in multiparametric MRI (mpMRI) (T2-weighted, Apparent Diffusion Coefficient (ADC), and Dynamic Contrast Enhanced (DCE-)MRI) of prostate cancer patients receiving Lattice Extreme Ablative Dose (LEAD) radiotherapy (RT) and the capability of their imaging features to predict RT outcome based on endpoint biopsies. Ninety-five mpMRI exams from 25 patients, acquired pre-RT and at 3-, 9-, and 24-months post-RT were analyzed. MRI/Ultrasound-fused biopsies were acquired pre- and at two-years post-RT (endpoint). Five regions of interest (ROIs) were analyzed: Gross tumor volume (GTV), normally-appearing tissue (NAT) and peritumoral volume in both peripheral (PZ) and transition (TZ) zones. Diffusion and perfusion radiomics features were extracted from mpMRI and compared before and after RT using two-tailed Student t-tests. Selected features at the four scan points and their differences (Δ radiomics) were used in multivariate logistic regression models to predict the endpoint biopsy positivity. Baseline ADC values were significantly different between GTV, NAT-PZ, and NAT-TZ (p-values < 0.005). Pharmaco-kinetic features changed significantly in the GTV at 3-month post-RT compared to baseline. Several radiomics features at baseline and three-months post-RT were significantly associated with endpoint biopsy positivity and were used to build models with high predictive power of this endpoint (AUC = 0.98 and 0.89, respectively). Our study characterized the RT-induced changes in perfusion and diffusion. Quantitative imaging features from mpMRI show promise as being predictive of endpoint biopsy positivity. MDPI 2022-09-15 /pmc/articles/PMC9496901/ /pubmed/36139635 http://dx.doi.org/10.3390/cancers14184475 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Algohary, Ahmad
Alhusseini, Mohammad
Breto, Adrian L.
Kwon, Deukwoo
Xu, Isaac R.
Gaston, Sandra M.
Castillo, Patricia
Punnen, Sanoj
Spieler, Benjamin
Abramowitz, Matthew C.
Dal Pra, Alan
Kryvenko, Oleksandr N.
Pollack, Alan
Stoyanova, Radka
Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy
title Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy
title_full Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy
title_fullStr Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy
title_full_unstemmed Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy
title_short Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy
title_sort longitudinal changes and predictive value of multiparametric mri features for prostate cancer patients treated with mri-guided lattice extreme ablative dose (lead) boost radiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496901/
https://www.ncbi.nlm.nih.gov/pubmed/36139635
http://dx.doi.org/10.3390/cancers14184475
work_keys_str_mv AT algoharyahmad longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT alhusseinimohammad longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT bretoadrianl longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT kwondeukwoo longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT xuisaacr longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT gastonsandram longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT castillopatricia longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT punnensanoj longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT spielerbenjamin longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT abramowitzmatthewc longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT dalpraalan longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT kryvenkooleksandrn longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT pollackalan longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy
AT stoyanovaradka longitudinalchangesandpredictivevalueofmultiparametricmrifeaturesforprostatecancerpatientstreatedwithmriguidedlatticeextremeablativedoseleadboostradiotherapy